{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:32Z","timestamp":1787003432865,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2013Brazil (CAPES)\u2013Finance Code 001","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["CNPq"],"award-info":[{"award-number":["CNPq"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation. In search of new pharmacological alternatives that minimize your symptoms, this work set out to study the effect of losartan (LOS), a receptor type I (AT1) angiotensin II antagonist, on intestinal mucositis induced by 5-FU. Intestinal mucositis was induced by a single intraperitoneal administration of 5-FU (450\u00a0mg\/kg) in Swiss mice. Losartan (5, 25 or 50\u00a0mg\/kg) or saline was orally administered 30\u00a0min before 5-FU and daily for 4\u00a0days. On 4th day, the animals were euthanized and segments of small intestine were collected to evaluate histopathological alterations (morphometric analysis), concentration of inflammatory cytokines, oxidative stress markers and genic expression of NF-\u03baB p65, Fn-14 and TWEAK. Weight evaluation and changes in leukogram were also analyzed. 5-FU induced intense weight loss, leukopenia and reduction in villus height compared to saline group. Losartan (50\u00a0mg\/kg) prevented 5-FU-induced inflammation by decreasing in the analyzed parameters compared to the 5-FU group. Our findings suggest that 50\u00a0mg\/kg of losartan prevents the effects of 5-FU on intestinal mucosa in mice.<\/jats:p>","DOI":"10.1038\/s41598-021-01969-x","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T06:04:42Z","timestamp":1638338682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Losartan improves intestinal mucositis induced by 5-fluorouracil in mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Maisie Mitchele Barbosa","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurigena Antunes","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana Barbosa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyana Crislayne Moreira","family":"de Sales Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria Barros","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concei\u00e7\u00e3o","family":"da Silva Martins Rebou\u00e7as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozi Godoy","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Batista","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerly Anne","family":"de Castro Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Ferreira","family":"de Carvalho Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlane Coelho Bernardo","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Addison Carvalho Xavier","family":"de Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"1969_CR1","volume":"124","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota. Biomed. Pharmacother. 124, 109829 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1969_CR2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fcimb.2017.00455","volume":"7","author":"HL Li","year":"2017","unstructured":"Li, H. L. et al. Alteration of gut microbiota and inflammatory cytokine\/chemokine profiles in 5-fluorouracil induced intestinal mucositis. Front. Cell Infect. Microbiol. 7, 455 (2017).","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"9","key":"1969_CR3","volume":"10","author":"CY Yeung","year":"2015","unstructured":"Yeung, C. Y. et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS\u00a0One 10(9), e0138746 (2015).","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1969_CR4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/SPC.0000000000000345","volume":"12","author":"J Arends","year":"2018","unstructured":"Arends, J. How to feed patients with gastrointestinal mucositis. Curr. Opin. Support. Palliat. Care 12(2), 168\u2013173 (2018).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"4","key":"1969_CR5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrc1318","volume":"4","author":"ST Sonis","year":"2004","unstructured":"Sonis, S. T. The pathobiology of mucositis. Nat. Rev. Cancer 4(4), 277\u2013284 (2004).","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"1969_CR6","volume":"7","author":"CT Chang","year":"2012","unstructured":"Chang, C. T. et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-kappaB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS\u00a0One 7(3), e31808 (2012).","journal-title":"PLoS\u00a0One"},{"key":"1969_CR7","volume":"124","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2\/MyD88\/NF-kB pathway and regulation of microbiota. Biomed. Pharmacother. 124, 109883 (2020).","journal-title":"Biomed. Pharmacother."},{"issue":"Suppl 5","key":"1969_CR8","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","volume":"26","author":"DE Peterson","year":"2015","unstructured":"Peterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., Herrstedt, J. & Committee, E. G. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 26(Suppl 5), v139\u2013v151 (2015).","journal-title":"Ann. Oncol."},{"issue":"3","key":"1969_CR9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-014-2663-x","volume":"75","author":"PF Justino","year":"2015","unstructured":"Justino, P. F. et al. Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice. Cancer Chemother. Pharmacol. 75(3), 559\u2013567 (2015).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"1969_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/SPC.0b013e32835f3e8c","volume":"7","author":"HR Wardill","year":"2013","unstructured":"Wardill, H. R. & Bowen, J. M. Chemotherapy-induced mucosal barrier dysfunction: An updated review on the role of intestinal tight junctions. Curr. Opin. Support. Palliat. Care 7(2), 155\u2013161 (2013).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"10","key":"1969_CR11","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00520-019-04893-z","volume":"27","author":"J Bowen","year":"2019","unstructured":"Bowen, J. et al. The pathogenesis of mucositis: Updated perspectives and emerging targets. Support. Care Cancer 27(10), 4023\u20134033 (2019).","journal-title":"Support. Care Cancer"},{"issue":"2","key":"1969_CR12","volume":"10","author":"C Focaccetti","year":"2015","unstructured":"Focaccetti, C. et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS\u00a0One 10(2), e0115686 (2015).","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"1969_CR13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/hr.2013.3","volume":"36","author":"I Taguchi","year":"2013","unstructured":"Taguchi, I. et al. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens. Res. 36(7), 608\u2013613 (2013).","journal-title":"Hypertens. Res."},{"issue":"1","key":"1969_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2006","unstructured":"Dandona, P., Dhindsa, S., Ghanim, H. & Chaudhuri, A. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 21(1), 20\u201327 (2006).","journal-title":"J. Hum. Hypertens."},{"issue":"4","key":"1969_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20110677","volume":"123","author":"M Horiuchi","year":"2012","unstructured":"Horiuchi, M., Iwanami, J. & Mogi, M. Regulation of angiotensin II receptors beyond the classical pathway. Clin. Sci. (Lond.) 123(4), 193\u2013203 (2012).","journal-title":"Clin. Sci. (Lond.)"},{"issue":"3","key":"1969_CR16","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","volume":"234","author":"R Ranjbar","year":"2019","unstructured":"Ranjbar, R. et al. The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases. J. Cell. Physiol. 234(3), 2277\u20132295 (2019).","journal-title":"J. Cell. Physiol."},{"key":"1969_CR17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3904\/kjim.2019.262","volume":"36","author":"HW Lee","year":"2021","unstructured":"Lee, H. W., Suh, J. K., Jang, E. & Lee, S. M. Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis. Korean J. Intern. Med. 36, 371\u2013381 (2021).","journal-title":"Korean J. Intern. Med."},{"key":"1969_CR18","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6156.1000615","author":"RS Padda","year":"2015","unstructured":"Padda, R. S., Shi, Y., Lo, C.-S., Zhang, S.-L. & Chan, J. S. D. Angiotensin-(1\u20137): A novel peptide to treat hypertension and nephropathy in diabetes?. J. Diabetes Metab. https:\/\/doi.org\/10.4172\/2155-6156.1000615 (2015).","journal-title":"J. Diabetes Metab."},{"issue":"2","key":"1969_CR19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s43440-019-00033-w","volume":"72","author":"AH Hasanin","year":"2020","unstructured":"Hasanin, A. H. & Mohamed, R. H. Telmisartan alone or in combination with etanercept improves anemia associated with rheumatoid arthritis in rats: A possible role of anti-inflammatory and reno-protective effects. Pharmacol. Rep. 72(2), 379\u2013388 (2020).","journal-title":"Pharmacol. Rep."},{"key":"1969_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.exger.2014.07.017","volume":"58","author":"CH Lin","year":"2014","unstructured":"Lin, C. H. et al. Losartan improves measures of activity, inflammation, and oxidative stress in older mice. Exp. Gerontol. 58, 174\u2013178 (2014).","journal-title":"Exp. Gerontol."},{"issue":"1","key":"1969_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12881-019-0918-4","volume":"20","author":"L Duan","year":"2019","unstructured":"Duan, L. et al. Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men harboring SLCO1B1*1b\/*1b while using aspirin and an ACEI or ARB concomitantly. BMC Med. Genet. 20(1), 183 (2019).","journal-title":"BMC Med. Genet."},{"issue":"4","key":"1969_CR22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/1534735418794885","volume":"17","author":"M Thomsen","year":"2018","unstructured":"Thomsen, M. & Vitetta, L. Adjunctive treatments for the prevention of chemotherapy- and radiotherapy-induced mucositis. Integr. Cancer Ther. 17(4), 1027\u20131047 (2018).","journal-title":"Integr. Cancer Ther."},{"key":"1969_CR23","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fphys.2018.01204","volume":"9","author":"MM Barbosa","year":"2018","unstructured":"Barbosa, M. M. et al. Telmisartan modulates the oral mucositis induced by 5-fluorouracil in hamsters. Front. Physiol. 9, 1204 (2018).","journal-title":"Front. Physiol."},{"issue":"12","key":"1969_CR24","volume":"9","author":"RF de Araujo Jr","year":"2014","unstructured":"de Araujo, R. F. Jr. et al. Olmesartan decreased levels of IL-1beta and TNF-alpha, down-regulated MMP-2, MMP-9, COX-2, RANK\/RANKL and up-regulated SOCs-1 in an intestinal mucositis model. PLoS\u00a0One 9(12), e114923 (2014).","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1969_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/ph12020051","volume":"12","author":"JAL de Miranda","year":"2019","unstructured":"de Miranda, J. A. L. et al. Protective effect of cashew gum (Anacardium occidentale L.) on 5-fluorouracil-induced intestinal mucositis. Pharmaceuticals (Basel) 12(2), 51 (2019).","journal-title":"Pharmaceuticals (Basel)"},{"key":"1969_CR26","volume":"118","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Qingjie Fuzheng Granule attenuates 5-fluorouracil-induced intestinal mucosal damage. Biomed. Pharmacother. 118, 109223 (2019).","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"1969_CR27","doi-asserted-by":"crossref","first-page":"G712","DOI":"10.1152\/ajpgi.00380.2020","volume":"320","author":"AT Sougiannis","year":"2021","unstructured":"Sougiannis, A. T., VanderVeen, B. N., Davis, J. M., Fan, D. & Murphy, E. A. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am. J. Physiol. Gastrointest. Liver Physiol. 320(5), G712\u2013G719 (2021).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1969_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.toxrep.2015.10.010","volume":"3","author":"EX Dos Santos Filho","year":"2016","unstructured":"Dos Santos Filho, E. X. et al. Curcuminoids from Curcuma longa L. reduced intestinal mucositis induced by 5-fluorouracil in mice: Bioadhesive, proliferative, anti-inflammatory and antioxidant effects. Toxicol. Rep. 3, 55\u201362 (2016).","journal-title":"Toxicol. Rep."},{"issue":"1","key":"1969_CR29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-018-36878-z","volume":"9","author":"DVS Costa","year":"2019","unstructured":"Costa, D. V. S. et al. 5-Fluorouracil induces enteric neuron death and glial activation during intestinal mucositis via a S100B-RAGE-NFkappaB-dependent pathway. Sci. Rep. 9(1), 665 (2019).","journal-title":"Sci. Rep."},{"issue":"6","key":"1969_CR30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/cancers11060857","volume":"11","author":"D Basile","year":"2019","unstructured":"Basile, D. et al. Mucosal injury during anti-cancer treatment: From pathobiology to bedside. Cancers (Basel) 11(6), 857 (2019).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1969_CR31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.116.237586","volume":"360","author":"GS Patten","year":"2017","unstructured":"Patten, G. S. & Abeywardena, M. Y. Effects of antihypertensive agents on intestinal contractility in the spontaneously hypertensive rat: Angiotensin receptor system downregulation by losartan. J. Pharmacol. Exp. Ther. 360(2), 260\u2013266 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"1969_CR32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00383-008-2277-7","volume":"24","author":"H Koga","year":"2008","unstructured":"Koga, H., Yang, H., Haxhija, E. Q. & Teitelbaum, D. H. The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. Pediatr. Surg. Int. 24(12), 1279\u20131286 (2008).","journal-title":"Pediatr. Surg. Int."},{"issue":"1","key":"1969_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1748-1716.2010.02165.x","volume":"201","author":"L Fandriks","year":"2011","unstructured":"Fandriks, L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol. (Oxf.) 201(1), 157\u2013167 (2011).","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"3","key":"1969_CR34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"AC Simoes e Silva","year":"2013","unstructured":"Simoes e Silva, A. C., Silveira, K. D., Ferreira, A. J. & Teixeira, M. M. ACE2, angiotensin-(1\u20137) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol. 169(3), 477\u2013492 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"1969_CR35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","volume":"107","author":"ESAC Simoes","year":"2016","unstructured":"Simoes, E. S. A. C. & Teixeira, M. M. ACE inhibition, ACE2 and angiotensin-(1\u20137) axis in kidney and cardiac inflammation and fibrosis. Pharmacol. Res. 107, 154\u2013162 (2016).","journal-title":"Pharmacol. Res."},{"issue":"2","key":"1969_CR36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3892\/mmr.2015.4686","volume":"13","author":"TJ Liu","year":"2016","unstructured":"Liu, T. J., Shi, Y. Y., Wang, E. B., Zhu, T. & Zhao, Q. AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn\u2019s disease. Mol. Med. Rep. 13(2), 1156\u20131162 (2016).","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"1969_CR37","volume":"6","author":"Y Shi","year":"2016","unstructured":"Shi, Y. et al. Activation of the renin\u2013angiotensin system promotes colitis development. Sci. Rep. 6(1), 27552 (2016).","journal-title":"Sci. Rep."},{"issue":"3","key":"1969_CR38","volume":"11","author":"MA Khajah","year":"2016","unstructured":"Khajah, M. A., Fateel, M. M., Ananthalakshmi, K. V. & Luqmani, Y. A. Anti-inflammatory action of angiotensin 1\u20137 in experimental colitis. PLoS\u00a0One 11(3), e0150861 (2016).","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"1969_CR39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00280-010-1409-7","volume":"67","author":"CA Medeiros","year":"2011","unstructured":"Medeiros, C. A. et al. Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. Cancer Chemother. Pharmacol. 67(5), 1085\u20131100 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"1969_CR40","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/bph.14987","volume":"177","author":"T Boeing","year":"2020","unstructured":"Boeing, T. et al. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties. Br. J. Pharmacol. 177(10), 2393\u20132408 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"1969_CR41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fphar.2017.00354","volume":"8","author":"M Cinausero","year":"2017","unstructured":"Cinausero, M. et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017).","journal-title":"Front. Pharmacol."},{"issue":"4","key":"1969_CR42","first-page":"995","volume":"10","author":"KO Oyedeji","year":"2018","unstructured":"Oyedeji, K. O., Okeke, O. E., Talabi, Y. J. & Gboluwagwa, O. Effect of losartan (angiotensin II antagonist) on haematological and biochemical parameters in male Wistar rats. J. Pharm. Sci. Res. 10(4), 995\u2013998 (2018).","journal-title":"J. Pharm. Sci. Res."},{"key":"1969_CR43","first-page":"506","volume":"20","author":"M Hashemzehi","year":"2021","unstructured":"Hashemzehi, M. et al. Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer. EXCLI J. 20, 506\u2013521 (2021).","journal-title":"EXCLI J."},{"key":"1969_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.peptides.2013.05.012","volume":"46","author":"KD Silveira","year":"2013","unstructured":"Silveira, K. D. et al. Mechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritis. Peptides 46, 53\u201363 (2013).","journal-title":"Peptides"},{"issue":"4","key":"1969_CR45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/pr.2016.266","volume":"81","author":"E Suganuma","year":"2017","unstructured":"Suganuma, E. et al. Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. Pediatr. Res. 81(4), 593\u2013600 (2017).","journal-title":"Pediatr. Res."},{"issue":"8","key":"1969_CR46","volume":"11","author":"D Karanovic","year":"2016","unstructured":"Karanovic, D. et al. Effects of single and combined losartan and tempol treatments on oxidative stress, kidney structure and function in spontaneously hypertensive rats with early course of proteinuric nephropathy. PLoS\u00a0One. 11(8), e0161706 (2016).","journal-title":"PLoS\u00a0One."},{"issue":"2","key":"1969_CR47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/cells9020405","volume":"9","author":"N Mendez-Barbero","year":"2020","unstructured":"Mendez-Barbero, N., Gutierrez-Munoz, C., Blazquez-Serra, R., Martin-Ventura, J. L. & Blanco-Colio, L. M. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)\/fibroblast growth factor-inducible 14 (Fn14) axis in cardiovascular diseases: Progress and challenges. Cells 9(2), 405 (2020).","journal-title":"Cells"},{"issue":"1","key":"1969_CR48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1748-1716.2010.02080.x","volume":"199","author":"E Mustonen","year":"2010","unstructured":"Mustonen, E. et al. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol. (Oxf.) 199(1), 11\u201322 (2010).","journal-title":"Acta Physiol. (Oxf.)"},{"issue":"3","key":"1969_CR49","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2008.11.017","volume":"136","author":"T Dohi","year":"2009","unstructured":"Dohi, T. et al. TWEAK\/Fn14 pathway: A nonredundant role in intestinal damage in mice through a TWEAK\/intestinal epithelial cell axis. Gastroenterology 136(3), 912\u2013923 (2009).","journal-title":"Gastroenterology"},{"issue":"2","key":"1969_CR50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1189\/jlb.0112042","volume":"92","author":"T Dohi","year":"2012","unstructured":"Dohi, T. & Burkly, L. C. The TWEAK\/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: Focus on inflammatory bowel diseases. J. Leukoc. Biol. 92(2), 265\u2013279 (2012).","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"1969_CR51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcmgh.2019.05.009","volume":"8","author":"L Di Martino","year":"2019","unstructured":"Di Martino, L., Osme, A., Kossak-Gupta, S., Pizarro, T. T. & Cominelli, F. TWEAK\/Fn14 is overexpressed in Crohn\u2019s disease and mediates experimental ileitis by regulating critical innate and adaptive immune pathways. Cell. Mol. Gastroenterol. Hepatol. 8(3), 427\u2013446 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1969_CR52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-230X-11-90","volume":"11","author":"RF Leitao","year":"2011","unstructured":"Leitao, R. F. et al. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol. 11, 90 (2011).","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"1969_CR53","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00280-011-1780-z","volume":"69","author":"RC Lima-Junior","year":"2012","unstructured":"Lima-Junior, R. C. et al. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother. Pharmacol. 69(4), 931\u2013942 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"1969_CR54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/ph13110361","volume":"13","author":"DVS Costa","year":"2020","unstructured":"Costa, D. V. S. et al. The alpha-lipoic acid improves survival and prevents irinotecan-induced inflammation and intestinal dysmotility in mice. Pharmaceuticals (Basel) 13(11), 361 (2020).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1969_CR55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00280-010-1540-5","volume":"68","author":"PM Soares","year":"2011","unstructured":"Soares, P. M. et al. Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Cancer Chemother. Pharmacol. 68(3), 713\u2013720 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"1969_CR56","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jcpe.12160","volume":"40","author":"AA Araujo","year":"2013","unstructured":"Araujo, A. A. et al. Effect of telmisartan on levels of IL-1, TNF-alpha, down-regulated COX-2, MMP-2, MMP-9 and RANKL\/RANK in an experimental periodontitis model. J. Clin. Periodontol. 40(12), 1104\u20131111 (2013).","journal-title":"J. Clin. Periodontol."},{"key":"1969_CR57","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2020.104664","volume":"111","author":"M Sousa Gomes","year":"2020","unstructured":"Sousa Gomes, M. et al. Anti-inflammatory and antioxidant activity of hydroethanolic extract of Spondias mombin leaf in an oral mucositis experimental model. Arch. Oral Biol. 111, 104664 (2020).","journal-title":"Arch. Oral Biol."},{"key":"1969_CR58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0003-2697(68)90092-4","volume":"25","author":"J Sedlak","year":"1968","unstructured":"Sedlak, J. & Lindsay, R. H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman\u2019s reagent. Anal. Biochem. 25, 192\u2013205 (1968).","journal-title":"Anal. Biochem."},{"issue":"6","key":"1969_CR59","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0891-5849(03)00388-5","volume":"35","author":"I Rebrin","year":"2003","unstructured":"Rebrin, I., Kamzalov, S. & Sohal, R. S. Effects of age and caloric restriction on glutathione redox state in mice. Free Radic. Biol. Med. 35(6), 626\u2013635 (2003).","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"1969_CR60","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao, X., Huang, X., Zhou, Z. & Lin, X. An improvement of the 2(\u2212delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat. Bioinform. Biomath. 3(3), 71\u201385 (2013).","journal-title":"Biostat. Bioinform. Biomath."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01969-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:40:20Z","timestamp":1670071220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01969-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01969-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23241"}}